NovaBay Pharmaceuticals, Inc.
NBY
$1.03
$0.4371.67%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 8.60% | -1.90% | -32.25% |
| Total Other Revenue | -- | -- | 89.29% | 70.00% | 18.18% |
| Total Revenue | -- | -- | 9.90% | -1.61% | -32.09% |
| Cost of Revenue | -- | -- | -20.73% | 3.54% | -- |
| Gross Profit | -- | -- | 38.69% | -4.15% | -- |
| SG&A Expenses | 16.94% | 17.90% | 32.87% | 12.48% | -41.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.94% | 17.90% | 15.73% | 10.16% | -64.73% |
| Operating Income | -16.94% | -17.90% | -27.88% | -52.01% | -53.85% |
| Income Before Tax | 8.61% | -13.85% | 23.04% | 10.42% | -24.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.61% | -13.85% | 23.04% | 10.42% | -24.36% |
| Earnings from Discontinued Operations | -92.55% | 3,906.23% | 104.65% | -- | 283.12% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.26% | 338.64% | 70.50% | 31.02% | 22.15% |
| EBIT | -16.94% | -17.90% | -27.88% | -52.01% | -53.85% |
| EBITDA | -17.32% | -18.43% | -28.61% | -53.58% | -55.20% |
| EPS Basic | 75.92% | 104.82% | 99.67% | 95.44% | 96.90% |
| Normalized Basic EPS | 81.13% | 97.93% | 98.10% | 96.80% | 90.79% |
| EPS Diluted | 75.75% | 104.82% | 99.67% | 95.44% | 96.90% |
| Normalized Diluted EPS | 81.13% | 97.97% | 98.10% | 96.80% | 90.79% |
| Average Basic Shares Outstanding | 403.72% | 4,323.33% | 3,956.32% | 2,668.66% | 1,169.23% |
| Average Diluted Shares Outstanding | 403.72% | 4,412.50% | 3,956.32% | 2,668.66% | 1,169.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |